March 2020 Report
New Drug Pipeline
| Medication (Trade Name) | Drug Class | Therapeutic Use | Status Update |
|---|---|---|---|
| Rimegepant (Nurtec™ ODT) | CGRP Antagonist | Migraine Headache Treatment | Approved February 27, 2020. |
| Buprenorphine/Naloxone (Cassipa®) |
Opioid Agonist/Antagonist | Opioid Misuse Disorder | Launch pending. Approved September 7, 2018. |
| Benzhydrocodone HCl/ Acetaminophen (Apadaz™) |
Opioid Analgesic – Immediate Release |
Pain | Launch pending. Approved February 23, 2018. |
| Buprenorphine Depot Injection (Brixadi™) |
Opioid Agonist | Treatment of Opioid Addiction |
Anticipated approval December 1, 2020 following expiration of exclusivity period for Sublocade™. |
| Celecoxib/Tramadol | NSAID/Opioid Agonist | Pain | FDA review pending. |
| Eptinezumab | CGRP Antagonist | Migraine Headache Prevention | FDA review pending. |
| Rimegepant (Zydis®) | CGRP Antagonist | Migraine Headache Prevention | FDA review pending. |
| Oxycodone HCl (Aximris XR™) | Opioid Analgesic – Extended Release |
Pain | FDA advisory committee recommended against approval. |
| Naloxone Injection (Zimhi™) | Opioid Antagonist | Opioid Overdose | FDA declined to approve November 2019. |
| Oxycodone HCl/ Naltrexone HCl (SequestOx™) |
Opioid Analgesic – Immediate Release |
Pain | FDA review pending after declining to approve in 2016. |
Generic Pipeline
| Medication (Trade Name) | Drug Class | Therapeutic Use | Status Update |
|---|---|---|---|
| Apixaban (Eliquis®) | Anticoagulant | Treatment/Prophylaxis of Deep Vein Thrombosis | Generics approved December 23, 2019, but settlements expected to delay launch for at least a few years. |
| Naloxone HCl (Narcan®) Nasal Spray |
Opioid Antidote | Opioid Overdose | Launch pending. Generic approved April 19, 2019. |
| Emtricitabine/Trenofovir (Truvada®) |
Antiretroviral | HIV Post-Exposure Prophylaxis | Generic anticipated late 2020 |
Available in the Last 12 Months
| Medication (Trade Name) | Drug Class | Therapeutic Use | Status Update |
|---|---|---|---|
| Ubrogepant (Ubrelvy™) | CGRP Antagonist | Migraine Headache Treatment | March 2020 |
| Lasmiditan (Reyvow™) | Migraine Agent | Migraine Headache Treatment | January 2020 |
| Sumatriptan Nasal Spray (Tosymra™) | Migraine Agent | Migraine Headache Treatment | October 2019 |
| Solriamfetol (Sunosi™) |
Stimulant | Excessive Sleepiness | July 2019 |
| Meloxicam (Qmiiz™ ODT) |
NSAID | Pain | April 2019 |
| Esketamine Nasal Spray (Spravato®) |
Antidepressant | Treatment Resistant Depression | March 2019 |
Newly Available Generics
| Medication (Trade Name) | Drug Class | Therapeutic Use | Status Update |
|---|---|---|---|
| Naproxen/Esomeprazole (Vimovo®) | NSAID/GI Protectant | Pain/Stomach Ulcer Prophylaxis | February 2020 |
| Albuterol Sulfate (ProAir® HFA) | Inhaled Bronchodilator | Asthma | February 2020 |
| Hydrocodone Bitartrate (Zohydro® ER) | Opioid Analgesic – Extended Release | Pain | January 2020 |
| Doxepin (Silenor®) | Tricyclic Antidepressant | Sleep Disorders | January 2020 |
| Pregabalin (Lyrica®) |
Anticonvulsant | Neuropathic Pain | July 2019 |
| Cyclobenzaprine HCl (Amrix®) |
Skeletal Muscle Relaxant | Muscle Spasm | March 2019 |
Discontinuations
| Medication (Trade Name) | Drug Class | Therapeutic Use | Status Update |
|---|---|---|---|
| Morphine Sulfate/Naltrexone HCl (Embeda®) | Opioid Analgesic – Extended Release Abuse Deterrent | Pain | Stop sale date November 15, 2019 with anticipated unavailability early 2020. |